Company / Capital Expenditures
Organon & Co. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$162.0M
FY2025
5-year range
$92.0M / $251.0M
FY2021-FY2025
Trend
-7.4%
vs FY2024
Sector context
#18 of 194
Health Care
What the data says
Among 194 Health Care companies, Organon & Co. is in the top 9% for capital expenditures. Capital Expenditures has fluctuated over the past 7 years, ranging from $92M in FY2021 to $255M in FY2020.
Based on SEC 10-K filings.
$162M in FY2025 with a 5-year CAGR of -8.7%. Top quartile in the Health Care sector.
Declined from $251M to $162M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -6.2%
- 5-Year CAGR
- -8.7%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 194This company $162.0M Sector average $117.5M
▼
+37.9% above sector average
Key checks
Key Insights
- 5-year CAGR of -8.7%, indicating a declining trend.
- In FY2025, capital expenditures decreased 7.4% year-over-year.
- Ranks #18 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $162.0M | -7.4% |
| FY2024 | $175.0M | -30.3% |
| FY2023 | $251.0M | +28.1% |
| FY2022 | $196.0M | +113.0% |
| FY2021 | $92.0M | -63.9% |
| FY2020 | $255.0M | +177.2% |
| FY2019 | $92.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026